Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/143534
Author(s): Taheri, Y
Suleria, HAR
Martins, N
Sytar, O
Beyatli, A
Yeskaliyeva, B
Seitimova, G
Salehi, B
Semwal, P
Painuli, S
Kumar, A
Azzini, E
Martorell, M
Setzer, WN
Maroyi, A
Sharifi-Rad, J
Title: Myricetin bioactive effects: Moving from preclinical evidence to potential clinical applications
Publisher: BMC
Issue Date: 2020
Abstract: Several flavonoids have been recognized as nutraceuticals, and myricetin is a good example. Myricetin is commonly found in plants and their antimicrobial and antioxidant activities is well demonstrated. One of its beneficial biological effects is the neuroprotective activity, showing preclinical activities on Alzheimer, Parkinson, and Huntington diseases, and even in amyotrophic lateral sclerosis. Also, myricetin has revealed other biological activities, among them as antidiabetic, anticancer, immunomodulatory, cardiovascular, analgesic and antihypertensive. However, few clinical trials have been performed using myricetin as nutraceutical. Thus, this review provides new insights on myricetin preclinical pharmacological activities, and role in selected clinical trials.
Subject: Antimicrobial
Antioxidant
Cancer
Cardiovascular disease
Diabetes
Immunomodulatory
Myricetin
Neuroprotection
DOI: 10.1186/s12906-020-03033-z
URI: https://hdl.handle.net/10216/143534
Source: BMC Complementary Medicine and Therapies, vol.20(1):241
Related Information: info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UID%2FBIM%2F04293%2F2013/PT
Document Type: Artigo em Revista Científica Internacional
Rights: openAccess
License: https://creativecommons.org/licenses/by/4.0/
https://creativecommons.org/publicdomain/zero/1.0/
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
10.1186-s12906-020-03033-z.pdf897.03 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons